Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their personal holdings in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing reports an increase in share interests for specific directors and connected persons following the re-investment of dividends paid on April 10, 2014. The transaction price was 1587.2087 pence per Ordinary Share. Specific increases include:
- Sir Andrew Witty: 4,120 shares
- Lady C Witty (Connected Person): 2,168 shares
- Mr I W Whyte: 207 shares
- Mrs V A Whyte: No change reported
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director shareholdings in compliance with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the dividend reinvestment price of 1587.2087 pence per share against market data for April 10, 2014.
- Confirm the updated total shareholdings for Sir Andrew Witty and other named directors post-transaction.
- Review the company's annual report (Form 20-F) for comprehensive financial performance data not included in this notification.